Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules. In VISTA, the regimen comprised four 6-week twice-weekly cycles, plus five 6-week onc...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	María-Victoria Mateos, Sara Bringhen, Paul G. Richardson, Juan Jose Lahuerta, Alessandra Larocca, Albert Oriol, Mario Boccadoro, Ramón García-Sanz, Francesco Di Raimondo, Dixie-Lee Esseltine, Helgi van de Velde, Avinash Desai, Anil Londhe, Jesús F. San Miguel, Antonio Palumbo
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Ferrata Storti Foundation 2014-06-01
Reeks:	Haematologica
Online toegang:	https://haematologica.org/article/view/7054
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!